Shares of Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) gapped down prior to trading on Wednesday. The stock had previously closed at $12.27, but opened at $11.80. Bavarian Nordic shares last traded at $11.80, with a volume of 142 shares changing hands.
Bavarian Nordic Price Performance
The stock has a market capitalization of $2.80 billion, a P/E ratio of 11.90 and a beta of 1.33. The stock’s fifty day moving average is $11.46 and its 200-day moving average is $10.19.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last posted its earnings results on Friday, August 21st. The company reported $0.46 earnings per share for the quarter. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%. The company had revenue of $316.47 million for the quarter.
Bavarian Nordic Company Profile
Bavarian Nordic is a Danish biotechnology company that develops, manufactures and markets vaccines for infectious diseases and cancer immunotherapy. Founded in 1994, the company is based in Denmark and serves markets in Europe, North America and other regions. Its best-known vaccine is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, for protection against smallpox and mpox. Bavarian Nordic also offers vaccines for diseases including rabies, tick-borne encephalitis, typhoid fever and cholera.
See Also
- Five stocks we like better than Bavarian Nordic
- Can Constellation Energy’s Contracts Power a Stock Rebound?
- Why Apple Stock Looks Like a Safe Haven After the Midterms
- IonQ Raised the Bar, But 3 Quantum Rivals Face Tough Questions
- On Holding’s Sell-Off Overlooks a Key Part of Its Earnings Story
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
